The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement
Abstract
DESCRIPTION: Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for diabetes in asymptomatic adults. METHODS: The USPSTF reviewed the evidence on screening for impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes in asymptomatic, nonpregnant adults who are at average or high risk for diabetes and its complications. POPULATION: This recommendation applies to adults aged 40 to 70 years seen in primary care settings who do not have symptoms of diabetes and are overweight or obese. RECOMMENDATION: The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity. (B recommendation).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive Behavioral Counseling (IBC) interventions like the National Diabetes Prevention Program (NDPP), have demonstrated effectiveness in reducing excess body weight and lowering or delaying morbidity onset.”
In the citing paper
“Intensive Behavioral Counseling (IBC) has been widely accepted as an effective approach for compliant individuals to reduce body weight, improve clinical measures, and lower risk of obesity-related comorbidities [1–6].”
In the citing paper
“The US Preventive Services Task Force (USPSTF) recommends that, as part of cardiovascular diseases (CVD) risk assessment, all overweight and obese adults between age 40 and 70 be screened for abnormal blood glucose, and those with CVD risk factors (e.g., hypertension, dyslipidemia, prediabetes) be referred for IBC, such as programs modeled on the National Diabetes Prevention Program (NDPP) [3,5].”
In the citing paper
“All individuals met the USPSTF criteria for receiving IBC because they had CVD risk factors independent of excess body weight; with 997 (89%) also meeting the CDC and NDPP recommendations for intervention due to prediabetes [3,5,17].”
In the citing paper
“Previous work has found that IBC intervention, including NDPP, among overweight and obese adults with prediabetes and CVD risk factors can improve clinical measures, prevent or delay disease onset, reduce medical expenditures, and increase productivity (in the form of higher labor force participation and lower work absenteeism) [1–6,13–15,19].”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“The Diabetes Prevention Program (11), conducted in the United States in 3234 participants, found that an intensive lifestyle modification intervention was associated with better quality of life at 3-year follow-up.”
BackgroundStandards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“Similarly, the Steno-2 Study (31) showed a reduction in all-cause mortality (RR, 0.”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., Li, H., Li, H., Jiang, Y., An, Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60766-7 · Cited by 1,600 · cited 3×
“One Finnish (12) and 1 Chinese (13) trial, each with more than 500 participants, suggested improvements in all-cause mortality outcomes after 10 and 20 years, respectively (HR, 0.”
BackgroundInfluentialEstacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N., & Schrier, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803053381003 · Cited by 1,166
Schrier, R. W., Estacio, R. O., Esler, A., & Mehler, P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00213.x · Cited by 851
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Davies, M. J., Heller, S., Skinner, T. C., Campbell, M. J., Carey, M. E., Cradock, S., Dallosso, H. M., Daly, H., Doherty, Y., Eaton, S., et al. (2008) · BMJ · doi:10.1136/bmj.39474.922025.be · Cited by 760
Li, G., Zhang, P., Wang, J., An, Y., Gong, Q., Gregg, E. W., Yang, W., Zhang, B., Shuai, Y., Hong, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70057-9 · Cited by 684 · cited 1×
“99]) in the intervention group compared with the control group (14).”
BackgroundEffect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Effect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · cited 1×
“The ADDITION-Europe trial (28, 29) evaluated the effects of intensive versus standard control of blood glucose levels, blood pressure, and lipid levels in a population with screen-detected diabetes (mean HbA1c level was 6.”
MethodBangalore, S., Kumar, S., Lobach, I., & Messerli, F. H. (2011) · Circulation · doi:10.1161/circulationaha.110.016337 · Cited by 437
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Herman, W. H., Ye, W., Griffin, S. J., Simmons, R. K., Davies, M. J., Khunti, K., Rutten, G. E. H. M., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2459 · Cited by 340
Canadian Task Force on Preventive Health Care
back, W., Birtwhistle, R., Fcfp, C., Pottie, K. C., MClSc, Shaw, E. A., Dickinson, J. A., Brauer, P. M., Fortin, M., Bell, N. R., et al. (2012) · Cited by 303
Screening for type 2 diabetes: literature review and economic modelling
Waugh, N., Scotland, G., McNamee, P., Gillett, M., Brennan, A., Goyder, E., Williams, R., & John, A. (2007) · Health Technology Assessment · doi:10.3310/hta11170 · Cited by 298
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Saito, T. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.275 · Cited by 277
Reboldi, G., Gentile, G., Angeli, F., Ambrosio, G., Mancia, G., & Verdecchia, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283469976 · Cited by 275
Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0959 · Cited by 256
Simmons, R. K., Echouffo-Tcheugui, J. B., Sharp, S. J., Sargeant, L. A., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61422-6 · Cited by 252
Howard, B. V. (2008) · JAMA · doi:10.1001/jama.299.14.1678 · Cited by 241
Uusitupa, M., Peltonen, M., Lindström, J., Aunola, S., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Valle, T. T., Eriksson, J. G., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2009) · PLoS ONE · doi:10.1371/journal.pone.0005656 · Cited by 215
Dagenais (2008) · doi:10.2337/dc07-1868 · Cited by 183
Recommendations on screening for type 2 diabetes in adults
Canadian Task Force on Preventive Health Care (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.120732 · Cited by 155
Selph, S., Dana, T., Blazina, I., Bougatsos, C., Patel, H., & Chou, R. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2221 · Cited by 134
Araki, A., Iimuro, S., Sakurai, T., Umegaki, H., Iijima, K., Nakano, H., Oba, K., Yokono, K., Sone, H., Yamada, N., et al. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00808.x · Cited by 80
Park, P., Simmons, R. K., Prevost, A. T., & Griffin, S. J. (2008) · BMC Public Health · doi:10.1186/1471-2458-8-350 · Cited by 76
Simmons, R. K., Rahman, M., Jakes, R. W., Yuyun, M. F., Niggebrugge, A., Hennings, S., Williams, D. R. R., Wareham, N. J., & Griffin, S. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1949-8 · Cited by 64
Tajima, N., Kurata, H., Nakaya, N., Mizuno, K., Ohashi, Y., Kushiro, T., Teramoto, T., Uchiyama, S., & Nakamura, H. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.027 · Cited by 54
Nijpels, G., Boorsma, W., Dekker, J. M., Kostense, P. J., Bouter, L. M., & Heine, R. J. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.839 · Cited by 45
Stavrakis, S., Thadani, U., Azar, M., Wayangankar, S. A., & Stoner, J. A. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181f1fba8 · Cited by 42
Paddison, C. A. M., Eborall, H., French, D., Kinmonth, A. L., Prevost, A. T., Griffin, S. J., & Sutton, S. R. (2010) · British Journal of Health Psychology · doi:10.1348/135910710x495366 · Cited by 37
Rahman, M., Simmons, R. K., Hennings, S., Wareham, N. J., & Griffin, S. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03570.x · Cited by 32
Badawi, A. F., Mortaz, Wessman, Duncan, & Gray (2012) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s30547 · Cited by 25
Simmons, R. K., Sharp, S. J., Sandbæk, A., Borch‐Johnsen, K., Davies, M. J., Khunti, K., Lauritzen, T., Rutten, G. E. H. M., van den Donk, M., Wareham, N. J., et al. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03759.x · Cited by 22
A1C to Detect Diabetes in Healthy Adults
Takahashi, O., Farmer, A. A., Shimbo, T., Fukui, T., & Glasziou, P. (2010) · Diabetes Care · doi:10.2337/dc10-0588 · Cited by 22
Selph, S., Dana, T., Bougatsos, C., Blazina, I., Patel, H., & Chou, R. (2015) · Europe PMC (PubMed Central) · Cited by 20
Research works printed but not linked: 3
- Mortaz S, 2012, Clinicoecon Outcomes Res, 4, 91
- Hemmingsen B, 2013, Cochrane Database Syst Rev, 11, CD008143
- American Diabetes Association, 2015, Diabetes Care, 38, S1
Cited by
Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319352 · Cited by 659
Diabetes 2030: Insights from Yesterday, Today, and Future Trends
Rowley, W. R., Bezold, C., Arikan, Y., Byrne, E., & Krohe, S. (2017) · Population Health Management · doi:10.1089/pop.2015.0181 · Cited by 655
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Kemper, A. R., Krist, A. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.15450 · Cited by 589
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Grossman, D. C., et al. (2018) · JAMA · doi:10.1001/jama.2018.13022 · Cited by 563
Elmets, C. A., Leonardi, C. L., Davis, D. M. R., Gelfand, J. M., Lichten, J., Mehta, N. N., Armstrong, A. W., Connor, C., Cordoro, K. M., Elewski, B. E., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.058 · Cited by 503
Metadata
- Authors
- Siu, A. L., & on behalf of the U.S. Preventive Services Task Force*
- Affiliations
- United States Preventive Services Task Force (US)
- Corresponding author
- Siu, Albert L.
- ORCID
- Siu, Albert L.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-12-01
- Volume
- 163
- Issue
- 11
- Pages
- 861-868
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2184512969
- Semantic Scholar
- d2283e77e36b23e882188941e6140255c0dc9669
- Cited by
- 319
- References
- 49
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 16 · 2023: 30 · 2022: 16 · 2021: 56 · 2020: 40 · 2019: 27 · 2018: 39 · 2017: 42 · 2016: 32 · 2015: 1
- FWCI
- 40.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes screening, impaired fasting glucose, impaired glucose tolerance, abnormal blood glucose, asymptomatic adults, overweight and obesity, cardiovascular risk assessment, behavioral counseling, primary care
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Mass Screening, Middle Aged, Cost of Illness, Risk Assessment, Glucose Metabolism Disorders, Asymptomatic Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.